Fortis Healthcare Limited has informed the Exchange regarding 'Disclosure Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 ( SEBI Listing Regulations ) - a Material Litigation Filed By Northern TK Venture Pte Ltd. ( NTK ), The Promoter Shareholder Of The Company, Against Daiichi Sankyo Company Limited Before The Tokyo District Court In Japan.'.
FORTIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Midcap 150 and 2.1 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Fortis Healthcare has shared an update from its Malaysian parent IHH Healthcare Berhad about an ongoing legal case in Japan. Northern TK Venture Pte Ltd (NTK), which is Fortis's promoter shareholder and an indirect subsidiary of IHH, had filed a material lawsuit against Daiichi Sankyo Company Limited before the Tokyo District Court. The court has now finished the preparatory and oral hearings in this case. The judgment date has been set for September 10, 2026. This case is connected to the historical dispute between the former promoters (Singh brothers) and Daiichi Sankyo over the Ranbaxy acquisition, where Daiichi Sankyo had won an arbitration award against the Singh brothers. The outcome could affect the encumbered shares and promoter holding in Fortis.
No immediate financial impact on Fortis's operations, but the September 2026 judgment is a key event to watch. A favourable outcome for NTK could strengthen the promoter's position, while an adverse ruling may create uncertainty around the ownership and encumbrance of promoter-held shares in Fortis.